Clinical Trial

Prediction of Targeted Therapy Efficacy in EGFR-mutant Lung Cancer Patients Using AI-based Multimodal Data

Not Yet Recruiting
View on ClinicalTrials.gov →
Summary
The main purpose of this study is to explore the value of multimodal imaging information and models in predicting the prognosis of EGFR-positive non-small cell lung cancer patients undergoing targeted therapy, providing a basis for selecting suitable populations for precise tumor treatment and corresponding therapy. We retrospectively analyzed patient case data, extracted preoperative CT images, H\&E-stained whole-slide digital pathology images, and pre- or postoperative genetic testing reports to extract radiomic features of tumor and peritumoral regions. These features were combined with multidimensional pathological features and gene expression distribution characteristics to construct a multimodal radiopathogenomic model, offering more precise prognostic evaluation for lung cancer patients receiving targeted therapy.
Trial Details
NCT Number NCT07287904
Lead Sponsor Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Conditions Lung Cancer (NSCLC), EGFR Activating Mutation, Adenocarcinoma Lung, Postoperative Adjuvant Therapy
Enrollment 1,000 participants
Start Date 2025-12-25
Primary Completion 2027-07 (estimated)
Study Completion 2027-08 (estimated)
Updated on ClinicalTrials.gov 2025-12-17